

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7372482

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	INNOVA BIOSCIENCES LTD	05/23/2022
RECEIVING PARTY DATA		
Name:	EXPEDEON LIMITED	
Street Address:	DISCOVERY DRIVE, CAMBRIDGE BIOMEDICAL CAMPUS	
City:	CAMBRIDGE	
State/Country:	UNITED KINGDOM	
Postal Code:	CB2 0AX	
PROPERTY NUMBERS Total: 4		
Property Type	Number	
Patent Number:	8492129	
Patent Number:	9176125	
Patent Number:	8877892	
Patent Number:	11046753	
CORRESPONDENCE DATA		
Fax Number:	(650)327-3231	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6503273400	
Email:	long@bozpat.com	
Correspondent Name:	BOZICEVIC, FIELD & FRANCIS LLP	
Address Line 1:	201 REDWOOD SHORES PARKWAY, SUITE 200	
Address Line 4:	REDWOOD CITY, CALIFORNIA 94065	
ATTORNEY DOCKET NUMBER:	BOULT-019, 020, 022, 023	
NAME OF SUBMITTER:	JAMES S. KEDDIE	
SIGNATURE:	/James S. Keddie/	
DATE SIGNED:	06/08/2022	
Total Attachments: 7		
source=BOULT-019, 020, 022, 023_executed assignment - Innova Bio and Expedeon Ltd#page1.tif		
source=BOULT-019, 020, 022, 023_executed assignment - Innova Bio and Expedeon Ltd#page2.tif		
source=BOULT-019, 020, 022, 023_executed assignment - Innova Bio and Expedeon Ltd#page3.tif		

source=BOULT-019, 020, 022, 023_executed assignment - Innova Bio and Expedeon Ltd#page4.tif
source=BOULT-019, 020, 022, 023_executed assignment - Innova Bio and Expedeon Ltd#page5.tif
source=BOULT-019, 020, 022, 023_executed assignment - Innova Bio and Expedeon Ltd#page6.tif
source=BOULT-019, 020, 022, 023_executed assignment - Innova Bio and Expedeon Ltd#page7.tif

THIS DEED OF ASSIGNMENT (the "Agreement") is made on 23 May 2022

BETWEEN:

- (1) **Innova Biosciences Ltd** a company incorporated in England and registered under company number 04415674, whose registered office is at Discovery Drive, Cambridge Biomedical Campus, Cambridge, CB2 0AX, United Kingdom (the "Assignor"), and whose former addresses are listed in Annex 1; and
- (2) **Expedeon Limited** a company incorporated in England and registered under company number 04681599, whose registered office is at Discovery Drive, Cambridge Biomedical Campus, Cambridge, CB2 0AX, United Kingdom (the "Assignee"), and whose former addresses are listed in Annex 2.

WHEREAS:

- (A) The Assignor is the registered proprietor of or applicant for (as applicable) the patents and patent applications described in the Schedule (the "Patents").
- (B) Pursuant to an agreement dated 1 March 2018 between the parties (the "Sale Agreement"), the Assignor has agreed, inter alia, to assign the patents to the Assignee, and the Assignee has agreed to accept this assignment, on the terms and for the consideration set out therein.

NOW IT IS HEREBY AGREED as follows:

1. ASSIGNMENT

- 1.1 In pursuance of the Sale Agreement and for the consideration contained therein, the Assignor hereby assigns to the Assignee, and the Assignee hereby accepts the assignment of:
 - 1.1.1 all its right, title and interest in the Patents;
 - 1.1.2 all its right title and interest in all and any inventions disclosed in the Patents;
 - 1.1.3 the right to claim priority from and to prosecute and obtain the grant of patent from any and each application in the Patents;
 - 1.1.4 the right to file divisional applications based on any and each application in the Patents and the right to obtain grant of patent on each and any such divisional application;
 - 1.1.5 in respect of each and any invention disclosed in any of the Patents, the right to file an application, claim priority from such application, and prosecute and obtain grant of patent or similar protection in or in respect of any country in the world;
 - 1.1.6 the right to extend to or register in or in respect of any country in the world each and any of the Patents, and each and any applications in the Patents and to extend to or register in, or in respect of, any country in the world any patent or similar protection on any such applications;
 - 1.1.7 the absolute entitlement to any patents granted pursuant to any of the applications in the Patents; and

- 1.1.8 the right to take action, bring, make, oppose, defend, appeal proceedings or claim and obtain damages and other remedies in respect of any infringement or any other cause of action arising from ownership of any of the Patents, patent applications or any patents granted from any of the applications in the Patents, whether occurring before, on or after the date of this Assignment.

2. NOTICES

- 2.1 Any notice or other communication given to a party under or in connection with this Agreement shall be in writing and shall be delivered by: (i) hand at its registered office; (ii) pre-paid first-class post or other next working day delivery service at its registered office; or (iii) email (including by attachment to an email) to the email address for that Party set out in clause 2.3.
- 2.2 Any notice or communication shall be deemed to have been received:
- 2.2.1 if delivered by hand, on signature of a delivery receipt;
- 2.2.2 if sent by pre-paid first-class post or other next working day delivery service, at 9.00 am on the second Business Day after posting; or
- 2.2.3 if sent by email, on receipt.
- 2.3 The email addresses for each of the Parties are:
- 2.3.1 In respect of the Assignor: legal@abcam.com; and
- 2.3.2 In respect of the Assignee: legal@abcam.com.

3. MISCELLANEOUS

Third party rights

- 3.1 No term of this Agreement is enforceable under the Contracts (Rights of Third Parties) Act 1999 by a person who is not a party to this Agreement and neither Party intends that this Agreement will benefit, or create any right or cause of action on behalf of, any person other than a Party hereto and no person, other than a Party hereto, will be entitled to rely on the provisions of this Agreement, including in any legal proceedings.

Variation

- 3.2 No variation of this Agreement shall be effective unless it is in writing (which for this purpose, does not include email) and signed by, or on behalf of, each of the Parties. The expression "variation" includes any variation, supplement, deletion or replacement however effected.

Counterparts

- 3.3 This Agreement may be executed in any number of counterparts and by the Parties to it on separate counterparts, each of which when executed and delivered shall be an original but all the counterparts together constitute one instrument.

Severance

3.4 If any provision or part of any provision of this Agreement is or becomes invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the validity or enforceability of that provision or of any other provision of this Agreement.

3.5 If any provision of this Agreement is or becomes invalid or unenforceable in any respect, but would be valid and enforceable if some part of the provision were deleted, the provision in question shall apply with such deletion as may be necessary to make it valid and enforceable.


4. GOVERNING LAW AND JURISDICTION

4.1 This Agreement and any dispute arising in connection with it shall be governed by and construed in accordance with English law.


4.2 Each Party irrevocably agrees that the Courts of England shall have exclusive jurisdiction in relation to any dispute arising in connection with this Agreement. Each Party irrevocably waives any right that it may have to object to an action being brought in those Courts, to claim that the action has been brought in an inconvenient forum, or to claim that those Courts do not have jurisdiction.

IN WITNESS whereof the parties have executed this Agreement as a deed the day and year first above written.

Executed as a deed by **Innova Biosciences Ltd** acting by Jonathan Fearn, a Director, in the presence of:



Director




Name: ANN FEARN


Address: 33 VERMUYDEN WAY, CB24 4TH.

Occupation: PA.

Executed as a deed by **Expedeon Limited** acting by Jonathan Fearn, a Director, in the presence of:



Director



Name: ANN FEARN

Address: 33 VERMUYDEN WAY, CB24 4TH

Occupation: PA.

SCHEDULE - THE PATENTS

Official No	Country	Title	Status
2014273034	Australia	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	Registered/Granted
3003385	Switzerland	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	Registered/Granted
71201480043061.4	China	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	Registered/Granted
DE602014053802	Germany	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	Registered/Granted
3003385	Europe	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	Inactive - End of European Phase
3003385	France	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	Registered/Granted
3003385	United Kingdom	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	Registered/Granted
2019-163553	Japan	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	Inactive - Abandoned
3003385	Netherlands	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	Registered/Granted
11046753	United States of America	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	Registered/Granted
PCT/EP2014/061281	PCT	ANTIBODY COMPOSITION AND BUFFER SYSTEM THEREFOR	Inactive - End of Intl Phase
2008263986	Australia	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	Registered/Granted
2688646	Canada	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	Registered/Granted
2171457	Switzerland	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	Registered/Granted
21200880103454.4	China	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	Registered/Granted
DE602008025932.3	Germany	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	Registered/Granted
2171457	Europe	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	Inactive - End of European Phase
2171457	France	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	Registered/Granted
2467041	United Kingdom	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	Registered/Granted
5444554	Japan	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	Registered/Granted
2171457	Netherlands	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	Registered/Granted
9176125	United States of America	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	Registered/Granted
PCT/GB2008/050438	PCT	IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES	Inactive - End of Intl Phase
2011222742	Australia	CONJUGATION REACTIONS	Registered/Granted
2791726	Canada	CONJUGATION REACTIONS	Registered/Granted

2566845	Switzerland	CONJUGATION REACTIONS	Registered/Granted
ZL201180022576.2	China	CONJUGATION REACTIONS	Registered/Granted
DE602011038184.9	Germany	CONJUGATION REACTIONS	Registered/Granted
2566845	Europe	CONJUGATION REACTIONS	Inactive - End of European Phase
2566845	France	CONJUGATION REACTIONS	Registered/Granted
2478359	United Kingdom	CONJUGATION REACTIONS	Registered/Granted
2566845	United Kingdom	CONJUGATION REACTIONS	Registered/Granted
6118560	Japan	CONJUGATION REACTIONS	Registered/Granted
8877892	United States of America	CONJUGATION REACTIONS	Registered/Granted
PCT/CB2011/050513	PCT	CONJUGATION REACTIONS	Inactive - End of Intl Phase
2006324488	Australia	PRODUCTION OF CONJUGATES	Registered/Granted
2630399	Canada	PRODUCTION OF CONJUGATES	Registered/Granted
1968641	Switzerland	PRODUCTION OF CONJUGATES	Registered/Granted
ZL200680046760.X	China	PRODUCTION OF CONJUGATES	Registered/Granted
DE602006041906.6	Germany	PRODUCTION OF CONJUGATES	Registered/Granted
1968641	Denmark	PRODUCTION OF CONJUGATES	Registered/Granted
1968641	Europe	PRODUCTION OF CONJUGATES	Inactive - End of European Phase
1968641	Spain	PRODUCTION OF CONJUGATES	Registered/Granted
1968641	Finland	PRODUCTION OF CONJUGATES	Registered/Granted
1968641	France	PRODUCTION OF CONJUGATES	Registered/Granted
2446088	United Kingdom	PRODUCTION OF CONJUGATES	Registered/Granted
1968641	Ireland	PRODUCTION OF CONJUGATES	Registered/Granted
1968641	Italy	PRODUCTION OF CONJUGATES	Registered/Granted
5380074	Japan	PRODUCTION OF CONJUGATES	Registered/Granted
1968641	Netherlands	PRODUCTION OF CONJUGATES	Registered/Granted
568386	New Zealand	PRODUCTION OF CONJUGATES	Registered/Granted
8492129	United States of America	PRODUCTION OF CONJUGATES	Registered/Granted
PCT/CB2006/004633	PCT	PRODUCTION OF CONJUGATES	Inactive - End of Intl Phase

Annex 1- Former addresses of Innova Biosciences Ltd:

- 25 Norman Way Industrial Estate, Norman Way, Over, Cambridge, CB24 5QE
 - (also referred to as 25 Norman Way, Over, Cambridge, CB24 5QE)
- Babraham Hall, Babraham, Cambridge, Cambridgeshire, CB22 3AT
 - (also referred to as Babraham Hall, Babraham, Cambridge, Cambs, CB22 3AT)
- Babraham Hall, Babraham, Cambridge, Cambridgeshire, CB2 4AT

Annex 2- Former addresses of Expedean Limited (previously known as Novexin Limited):

- 25 Norman Way Industrial Estate, Norman Way, Over, Cambridge, CB24 5QE
 - (also referred to as 25 Norman Way, Over, Cambridge, CB24 5QE)
- Unit 12 Buckingham Business Park, Anderson Road, Swavesey, Cambridge, Cambridgeshire, CB24 4AE
- Unit 1a Button End, Harston, Cambridge, CB22 7GX
- Babraham hall, Babraham, Cambridge, Cambridgeshire, CB22 3AT
 - (also referred to as Babraham Hall, Babraham, Cambridge, Cambs, CB22 3AT)
- Babraham hall, Babraham, Cambridge, Cambridgeshire, CB2 4AT
- Babraham biolncubator, Babraham, Cambridge, Cambridgeshire, CB2 4AT
- 171 High Street Cherry Hinton, Cambridge, Cambridgeshire, CB1 9LN
- 11 Sturton Street, Cambridge, Cambridgeshire, CB1 2SN